Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis. [electronic resource]
Producer: 20130925Description: 1491-502 p. digitalISSN:- 1433-2965
- Aged
- Aged, 80 and over
- Alendronate -- economics
- Algorithms
- Antibodies, Monoclonal, Humanized -- economics
- Bone Density Conservation Agents -- economics
- Cost-Benefit Analysis
- Denosumab
- Drug Costs -- statistics & numerical data
- Etidronic Acid -- analogs & derivatives
- Female
- Health Care Costs -- statistics & numerical data
- Humans
- Middle Aged
- Models, Econometric
- Osteoporosis, Postmenopausal -- drug therapy
- Osteoporotic Fractures -- economics
- Quality of Life
- RANK Ligand -- antagonists & inhibitors
- Risedronic Acid
- Risk Assessment -- methods
- Thiophenes -- economics
- United Kingdom -- epidemiology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.